- Home
- BMGL vs ACOG Comparison
BMGL vs ACOG Comparison
Compare BMGL & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMGL
- ACOG
- Stock Information
- Founded
- BMGL 2001
- ACOG 2000
- Country
- BMGL Singapore
- ACOG Canada
- Employees
- BMGL N/A
- ACOG N/A
- Industry
- BMGL
- ACOG
- Sector
- BMGL
- ACOG
- Exchange
- BMGL NYSE
- ACOG Nasdaq
- Market Cap
- BMGL 78.3M
- ACOG 80.3M
- IPO Year
- BMGL 2025
- ACOG N/A
- Fundamental
- Price
- BMGL $2.41
- ACOG $9.16
- Analyst Decision
- BMGL
- ACOG Strong Buy
- Analyst Count
- BMGL 0
- ACOG 1
- Target Price
- BMGL N/A
- ACOG $20.00
- AVG Volume (30 Days)
- BMGL 14.6M
- ACOG 130.0K
- Earning Date
- BMGL 01-01-0001
- ACOG 08-14-2025
- Dividend Yield
- BMGL N/A
- ACOG N/A
- EPS Growth
- BMGL 16.23
- ACOG N/A
- EPS
- BMGL 0.02
- ACOG N/A
- Revenue
- BMGL $7,342,469.00
- ACOG $2,928,654.00
- Revenue This Year
- BMGL N/A
- ACOG N/A
- Revenue Next Year
- BMGL N/A
- ACOG N/A
- P/E Ratio
- BMGL $125.57
- ACOG N/A
- Revenue Growth
- BMGL 3.32
- ACOG N/A
- 52 Week Low
- BMGL $0.91
- ACOG $3.75
- 52 Week High
- BMGL $9.40
- ACOG $11.40
- Technical
- Relative Strength Index (RSI)
- BMGL N/A
- ACOG N/A
- Support Level
- BMGL N/A
- ACOG N/A
- Resistance Level
- BMGL N/A
- ACOG N/A
- Average True Range (ATR)
- BMGL 0.00
- ACOG 0.00
- MACD
- BMGL 0.00
- ACOG 0.00
- Stochastic Oscillator
- BMGL 0.00
- ACOG 0.00
About BMGL BASEL MEDICAL GROUP LTD
Basel Medical Group Ltd provides general and subspecialized orthopedic, trauma and sports medicine services such as knee/hip replacements, sports medicine/surgery, spine surgery, foot/ankle surgery and minimally invasive orthopedic procedures, as well as neurosurgical treatments. Key revenue is generated from Singapore.
About ACOG Alpha Cognition Inc. Common Stock
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.